10x Genomics (NASDAQ:TXG – Get Free Report) and Many Bright Ideas Technologies (OTCMKTS:MBGNF – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.
Profitability
This table compares 10x Genomics and Many Bright Ideas Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 10x Genomics | -12.18% | -9.33% | -7.30% |
| Many Bright Ideas Technologies | N/A | N/A | N/A |
Earnings and Valuation
This table compares 10x Genomics and Many Bright Ideas Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 10x Genomics | $642.82 million | 12.47 | -$43.54 million | ($0.59) | -104.31 |
| Many Bright Ideas Technologies | N/A | N/A | N/A | N/A | N/A |
Many Bright Ideas Technologies has lower revenue, but higher earnings than 10x Genomics.
Insider and Institutional Ownership
84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and target prices for 10x Genomics and Many Bright Ideas Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 10x Genomics | 1 | 10 | 5 | 0 | 2.25 |
| Many Bright Ideas Technologies | 0 | 0 | 0 | 0 | 0.00 |
10x Genomics currently has a consensus price target of $38.31, suggesting a potential downside of 37.75%. Given 10x Genomics’ stronger consensus rating and higher probable upside, equities analysts plainly believe 10x Genomics is more favorable than Many Bright Ideas Technologies.
Summary
10x Genomics beats Many Bright Ideas Technologies on 6 of the 9 factors compared between the two stocks.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
About Many Bright Ideas Technologies
Many Bright Ideas Technologies Inc. does not have significant operations. It was previously engaged in the life science business with a focus on the commercialization of prognostic genomic-based tests for non-small-cell lung cancer. It focuses on the commercialization of technologies in various industrial sectors. The company is headquartered in Vancouver, Canada.
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
